Scholarlink

<p>Pilocytic astrocytomas (PAs) are rare primary brain tumors in adults and exhibit worse outcomes compared with pediatric cases. Surgery is the primary therapeutic approach, whereas radiation therapy (RT) is reserved for symptomatic recurrence but is associated with substantial long-term toxicity. PAs are characterized by the activation of the mitogen-activated protein kinase (MAPK) signaling pathway and Mitogen-activated protein kinase kinase (MEK) inhibitors have demonstrated effectivity in pediatric populations, though data in adults remain limited. We retrospectively analyzed data of five adult patients (ages 30–79), four with PAs and one with PA with anaplastic transformation, that were administered trametinib, a MEK1/2 inhibitor. All tumors harbored somatic <i>NF-1</i> mutations, with one germline NF-1 case. According to RANO 2.0 criteria, three patients achieved partial responses and two had stable disease, with neurological improvement in two cases. Median progression-free survival was 16.65 months, supporting MEK inhibition as an effective treatment strategy in adult PAs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

MEK inhibition in adult patients with pilocytic astrocytomas

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月16日

查看全文
  • Konstantinos Rounis,
  • Anna Falk Delgado,
  • Christopher Illies,
  • Alia Shamikh,
  • Theresa Wangerid,
  • Margret Jensdottir,
  • Jiri Bartek,
  • Oscar Persson,
  • Max Albert Hietala,
  • Signe Friesland,
  • Hanna Carstens,
  • Giuseppe Stragliotto

摘要

Pilocytic astrocytomas (PAs) are rare primary brain tumors in adults and exhibit worse outcomes compared with pediatric cases. Surgery is the primary therapeutic approach, whereas radiation therapy (RT) is reserved for symptomatic recurrence but is associated with substantial long-term toxicity. PAs are characterized by the activation of the mitogen-activated protein kinase (MAPK) signaling pathway and Mitogen-activated protein kinase kinase (MEK) inhibitors have demonstrated effectivity in pediatric populations, though data in adults remain limited. We retrospectively analyzed data of five adult patients (ages 30–79), four with PAs and one with PA with anaplastic transformation, that were administered trametinib, a MEK1/2 inhibitor. All tumors harbored somatic NF-1 mutations, with one germline NF-1 case. According to RANO 2.0 criteria, three patients achieved partial responses and two had stable disease, with neurological improvement in two cases. Median progression-free survival was 16.65 months, supporting MEK inhibition as an effective treatment strategy in adult PAs.